{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:54:46Z","timestamp":1789761286360,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ygyno.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T22:30:17Z","timestamp":1499553017000},"page":"484-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)\u2013only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer"],"prefix":"10.1016","volume":"146","author":[{"given":"Rebecca","family":"Kristeleit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Davidenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2475-9500","authenticated-orcid":false,"given":"Vadim","family":"Shirinkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"El-Khouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Goodheart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2550","authenticated-orcid":false,"given":"Vera","family":"Gorbunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Penning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack G.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Maleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.07.005_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0010","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0015","first-page":"537","article-title":"Clinical epidemiology of epithelial ovarian cancer in the UK","volume":"6","author":"Doufekas","year":"2014","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0030","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0035","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1200\/JCO.2005.01.6642","article-title":"Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer","volume":"23","author":"Menon","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0040","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2010.01.019","article-title":"Ovarian cancer creates a suppressive microenvironment to escape immune elimination","volume":"117","author":"Yigit","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14712590902932897","article-title":"Cellular immunotherapy for ovarian cancer","volume":"9","author":"Cannon","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0050","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0065","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0080","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0085","first-page":"1333","article-title":"Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer","volume":"17","author":"Takao","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0090","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.4049\/jimmunol.170.12.5809","article-title":"Tryptophan catabolism and regulation of adaptive immunity","volume":"170","author":"Mellor","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/GCO.0b013e3283409c79","article-title":"Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer","volume":"23","author":"Ino","year":"2011","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0100","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e14012","article-title":"The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro","volume":"33","author":"Jochems","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0110","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/jco.2012.30.15_suppl.2500","article-title":"Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients","volume":"30","author":"Newton","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0115","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/jco.2013.31.15_suppl.3025","article-title":"Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies","volume":"31","author":"Beatty","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0120","series-title":"AJCC Cancer Staging Manual","first-page":"419","article-title":"Ovary and primary peritoneal carcinoma","author":"Edge","year":"2010"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0125","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase 1 study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10408363.2011.599831","article-title":"Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer","volume":"48","author":"Allin","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143080","article-title":"C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review","volume":"10","author":"Shrotriya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0140","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/cts.12391","article-title":"Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities","volume":"9","author":"Morrissey","year":"2016","journal-title":"Clin. Trans. Sci."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0155","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2174\/092986711795656072","article-title":"Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases","volume":"18","author":"Prendergast","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0165","doi-asserted-by":"crossref","first-page":"P302","DOI":"10.1186\/2051-1426-3-S2-P302","article-title":"PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer","volume":"3","author":"Grabosch","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2017.07.005_bb0170","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/ijms17071169","article-title":"Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?","volume":"17","author":"Mittica","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2017.07.005_bb0175","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/jco.2014.32.15_suppl.3010","article-title":"Preliminary results from a phase 1\/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma","volume":"32","author":"Gibney","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817310223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817310223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:38:21Z","timestamp":1620826701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817310223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0090825817310223"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)\u2013only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}